Invasive Aspergillosis in Allogeneic Stem Cell Transplant Recipients: Increasing Antigenemia Is Associated with Progressive Disease

Citations Over TimeTop 10% of 2002 papers

Abstract

The kinetics of serum Aspergillus galactomannan, as determined by enzyme-linked immunosorbent assay, was examined in 37 allogeneic stem cell transplant (SCT) recipients treated for invasive aspergillosis (IA). Fifty-eight periods of response ("response episodes") were evaluated. There were 42 response episodes that were considered "treatment failures" and 16 that were considered "good" (that is, complete or partial) responses. At baseline (the first day of each new response episode), the patients who experienced treatment failure and those who had good responses did not differ significantly with regard to median galactomannan index (GMI) value. Thereafter, GMI values significantly increased in the treatment failure group, whereas no significant changes were observed in the good response group (P=.002). An increase in the GMI value of 1.0 over the baseline value during the first week of observation was predictive of treatment failure with a sensitivity of 44%, a specificity of 87%, and a positive predictive value of 94%. We conclude that serial determination of serum GMI values is a useful tool for assessing prognosis of IA in allogeneic SCT recipients during treatment.

Related Papers

• → Detection of Circulating Aspergillus fumigatus Galactomannan: Value and Limits of the Platelia Test for Diagnosing Invasive Aspergillosis(2003)146 cited
• → Assessment of a commercial sandwich ELISA in the diagnosis of aspergillosis in falcons(2006)30 cited
• [Usefulness of galactomannan detection in the diagnosis and follow-up of hematological patients with invasive aspergillosis].(2003)
• [Early diagnosis of invasive aspergillosis in neutropenic patients with bi-weekly serial screening of circulating galactomannan by Platelia Aspergillus].(2003)
• → Value of circulating galactomannan screening for early diagnosis of invasive aspergillosis in hematological patients(2011)2 cited